SCHEMBL6709580

SCHEMBL6709580

CC(C)c1cnc(N(C(N)=O)c2ccc3ccccc3n2)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.40
CYP1A2 P05177 3/20 0.40
PTGES O14684 1/20 0.40
LMNA P02545 1/20 0.40
LTA4H P09960 1/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
ALOX5AP P20292 1/20 0.40
LOX P28300 1/20 0.40
EPHX2 P34913 1/20 0.40
PTGS2 P35354 1/20 0.40
LTB4R Q15722 1/20 0.40
NCF1 P14598 1/20 0.38
CCNE1 P24864 6/20 0.38
CDK2 P24941 6/20 0.38
CDK5 Q00535 6/20 0.38
ALDH1A1 P00352 3/20 0.36
CCNT1 O60563 1/20 0.36
CDK1 P06493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27570602 0.81 ALOX5 (0.45) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL6711707 0.79 MLYCD (0.47) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL27570620 0.77 CCNE1 (0.40) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL27551055 0.77 ALOX5 (0.51) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL6716192 0.77 CCNE1 (0.39) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL14836709 0.76 NCF1 (0.53) CYP1A2LMNAGAANCF1ALDH1A1
SCHEMBL27551112 0.76 CCNE1 (0.40) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL27551198 0.76 CCNE1 (0.40) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL6710801 0.75 KDM4E (0.36) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL6716166 0.74 CCNE1 (0.37) ALOX5CYP1A2PTGESLMNALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN claimed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 ALOX5 4184/4885CYP1A2 3540/4885PTGES 4040/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 ALOX5 4184/4885CYP1A2 3540/4885PTGES 4040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.